AR103675A1 - Anticuerpos anti-ctla4 terapéuticos - Google Patents

Anticuerpos anti-ctla4 terapéuticos

Info

Publication number
AR103675A1
AR103675A1 ARP160100391A ARP160100391A AR103675A1 AR 103675 A1 AR103675 A1 AR 103675A1 AR P160100391 A ARP160100391 A AR P160100391A AR P160100391 A ARP160100391 A AR P160100391A AR 103675 A1 AR103675 A1 AR 103675A1
Authority
AR
Argentina
Prior art keywords
antibodies
diseases
ctla4
derivatives
fragments
Prior art date
Application number
ARP160100391A
Other languages
English (en)
Inventor
Zhou Heyue
Dixon Gray John
Original Assignee
Sorrento Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorrento Therapeutics Inc filed Critical Sorrento Therapeutics Inc
Publication of AR103675A1 publication Critical patent/AR103675A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composiciones y métodos relacionados o derivados de anticuerpos anti-CTLA4. Más específicamente, se divulgan anticuerpos completamente humanos que se unen a CTLA4, fragmentos de unión al anticuerpo CTLA4 y derivados de dichos anticuerpos, y polipéptidos de unión a CTLA4 que comprenden dichos fragmentos. Aún más, se divulgan ácidos nucleicos que codifican dichos anticuerpos, fragmentos de anticuerpo y derivados y polipéptidos, células que comprenden dichos polinucleótidos, métodos de elaboración de dichos anticuerpos, fragmentos de anticuerpo y derivados y polipéptidos, y métodos de uso de dichos anticuerpos, fragmentos de anticuerpo y derivados y polipéptidos, incluyendo métodos de tratamiento de una enfermedad que requiere ya sea estimulación o supresión de respuestas inmunológicas. La estimulación se logra usando anticuerpos que bloquean la unión de la CTLA4 humana a la B7 humana y las enfermedades susceptibles al tratamiento mediante estimulación y a un aumento de una prolongación de las respuestas inmunológicas incluyen cánceres de próstata, riñón, colon, pulmón o mama; infecciones patógenas; enfermedades asociadas con el SNC, por ejemplo enfermedades amiloidogénicas incluyendo el mal de Alzheimer; y enfermedades con componentes inflamatorios o alérgicos. Las enfermedades susceptibles de tratamiento incluyen enfermedad de injerto versus huésped, enfermedad de huésped versus injerto, alergia, enfermedades autoinmunes y otras enfermedades inflamatorias.
ARP160100391A 2015-02-13 2016-02-12 Anticuerpos anti-ctla4 terapéuticos AR103675A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562116353P 2015-02-13 2015-02-13

Publications (1)

Publication Number Publication Date
AR103675A1 true AR103675A1 (es) 2017-05-24

Family

ID=56614957

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160100391A AR103675A1 (es) 2015-02-13 2016-02-12 Anticuerpos anti-ctla4 terapéuticos

Country Status (13)

Country Link
US (3) US10202453B2 (es)
EP (3) EP3256165B1 (es)
JP (3) JP6917902B2 (es)
KR (1) KR20180006367A (es)
CN (2) CN108271359B (es)
AR (1) AR103675A1 (es)
AU (2) AU2016219170B2 (es)
CA (1) CA2976446A1 (es)
ES (1) ES2882157T3 (es)
IL (3) IL292578A (es)
MX (3) MX2017010412A (es)
TW (1) TW201636369A (es)
WO (2) WO2016130986A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160075772A1 (en) * 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
EP3256165B1 (en) * 2015-02-13 2021-07-14 Sorrento Therapeutics, Inc. Antibody therapeutics that bind ctla4
PT3303394T (pt) 2015-05-29 2020-07-01 Ludwig Inst For Cancer Res Ltd Anticorpos anti-ctla-4 e métodos de uso dos mesmos
MA42459A (fr) 2015-07-16 2018-05-23 Bioxcel Therapeutics Inc Nouvelle approche pour le traitement du cancer par immunomodulation
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
RU2756236C2 (ru) 2016-06-20 2021-09-28 Кимаб Лимитед PD-L1 специфические антитела
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
US10618962B2 (en) * 2016-10-10 2020-04-14 Crown Bioscience (Taicang) Inc. Anti-CTLA4 antibodies
AU2017373944B2 (en) 2016-12-07 2022-02-03 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
US11319372B2 (en) 2017-02-21 2022-05-03 Remd Biotherapeutics, Inc. Cancer treatment using antibodies that bind cytotoxic T-lymphocyte antigen-4 (CTLA-4)
EP3597735A4 (en) * 2017-03-15 2020-11-25 Suzhou Galaxy Biopharma, Co., Ltd. CTLA4 ANTIBODIES, PHARMACEUTICAL COMPOSITION AND USES THEREOF
EA201992755A1 (ru) * 2017-05-19 2020-04-22 Уси Байолоджикс (Шанхай) Ко. Лтд. Новые моноклональные антитела к белку 4, ассоциированному с цитотоксическими т-лимфоцитами, (ctla-4)
TWI799432B (zh) * 2017-07-27 2023-04-21 美商再生元醫藥公司 抗ctla-4抗體及其用途
WO2019036855A1 (en) 2017-08-21 2019-02-28 Adagene Inc. ANTI-CD137 MOLECULES AND THEIR USE
EP4295915A3 (en) * 2017-12-20 2024-05-22 Harbour Biomed (Shanghai) Co., Ltd Antibodies binding ctla-4 and uses thereof
WO2019148444A1 (en) * 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
CA3101614A1 (en) * 2018-05-31 2019-12-05 Sorrento Therapeutics, Inc. Drug delivery methods targeting the lymphatic system
US20210236547A1 (en) * 2018-06-05 2021-08-05 H. Lee Moffitt Cancer Center And Research Institute, Inc. Rapid production, expansion, and increased purity of car-t cells using beads with protein l
CN110760002A (zh) * 2018-07-25 2020-02-07 南京金斯瑞生物科技有限公司 人源化抗人ctla4单克隆抗体及其制备方法和用途
MX2021005048A (es) * 2018-10-31 2021-09-08 Bioatla Inc Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos.
US20230071889A1 (en) 2018-12-21 2023-03-09 Ose Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
SG11202106764YA (en) * 2018-12-27 2021-07-29 Gigagen Inc Anti-ctla-4 binding proteins and methods of use thereof
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
EP3996735A4 (en) * 2019-07-12 2023-07-19 The Research Foundation for The State University of New York COMPOSITIONS AND METHODS FOR BLOCKING AND BINDING CXCR4 TO MODULATE CELLULAR FUNCTION
WO2021122866A1 (en) 2019-12-17 2021-06-24 Ose Immunotherapeutics Bifunctional molecules comprising an il-7 variant
EP4110810A1 (en) 2020-02-28 2023-01-04 Orega Biotech Combination therapies based on ctla4 and il-17b inhibitors
WO2022112198A1 (en) 2020-11-24 2022-06-02 Worldwide Innovative Network Method to select the optimal immune checkpoint therapies
EP4320156A1 (en) 2021-04-09 2024-02-14 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
IL307419A (en) 2021-04-09 2023-12-01 Ose Immunotherapeutics A new scaffold for bifunctional molecules with improved properties
WO2024003360A1 (en) 2022-07-01 2024-01-04 Institut Curie Biomarkers and uses thereof for the treatment of neuroblastoma
WO2024028386A1 (en) 2022-08-02 2024-02-08 Ose Immunotherapeutics Multifunctional molecule directed against cd28

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3817827A (en) 1972-03-30 1974-06-18 Scott Paper Co Soft absorbent fibrous webs containing elastomeric bonding material and formed by creping and embossing
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
JP3051145B2 (ja) 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6887471B1 (en) * 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
CA2146559A1 (en) 1992-10-23 1994-05-11 Melanie K. Spriggs Methods of preparing soluble, oligomeric proteins
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2341029A1 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
EP2112166B1 (en) * 1998-12-23 2018-11-21 Pfizer Inc. Human monoclonal antibodies to ctla-4
DE60033530T2 (de) 1999-08-24 2007-10-31 Medarex Inc. Humane antikörper gegen ctla-4 und deren verwendungen
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
AU2001233027A1 (en) * 2000-01-27 2001-08-07 Genetics Institute, Llc Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
US6938003B2 (en) 2000-06-30 2005-08-30 Mahesh Harpale Method and apparatus for a credibility reporting system to augment an online exchange
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
IL149701A0 (en) * 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
WO2003086459A1 (en) * 2002-04-12 2003-10-23 Medarex, Inc. Methods of treatement using ctla-4 antibodies
JP4754219B2 (ja) * 2002-12-02 2011-08-24 アムジエン・フレモント・インコーポレイテツド 腫瘍壊死因子を対象とする抗体、およびそれらの使用
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
WO2005092380A2 (en) * 2004-03-26 2005-10-06 Pfizer Products Inc Uses of anti-ctla-4 antibodies
MX2007011767A (es) * 2005-03-23 2007-10-18 Pfizer Prod Inc Terapia de combinacion de anticuerpo anti-ctla4 e indolinona para el tratamiento del cancer.
CN101146552A (zh) * 2005-03-23 2008-03-19 辉瑞产品有限公司 用ctla4抗体和激素疗法治疗前列腺癌
WO2009100140A1 (en) * 2008-02-04 2009-08-13 Medarex, Inc. Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof
ES2545609T3 (es) * 2008-08-25 2015-09-14 Amplimmune, Inc. Composiciones de antagonistas de PD-1 y métodos de uso
SG10201609665PA (en) * 2011-02-25 2017-01-27 Chugai Pharmaceutical Co Ltd FcɣRIIb-SPECIFIC Fc ANTIBODY
GB201103955D0 (en) * 2011-03-09 2011-04-20 Antitope Ltd Antibodies
PL2900694T3 (pl) * 2012-09-27 2018-12-31 Merus N.V. Dwuswoiste przeciwciała igg jako aktywatory komórek t
EP3256165B1 (en) * 2015-02-13 2021-07-14 Sorrento Therapeutics, Inc. Antibody therapeutics that bind ctla4
US20170233476A1 (en) * 2016-02-12 2017-08-17 Sorrento Therapeutics, Inc. Antibody Therapeutics That Bind CTLA4

Also Published As

Publication number Publication date
IL284336B (en) 2022-06-01
WO2016130898A2 (en) 2016-08-18
EP3256165A2 (en) 2017-12-20
US11155623B2 (en) 2021-10-26
AU2021282431A1 (en) 2021-12-23
IL253963A0 (en) 2017-10-31
CN114014930A (zh) 2022-02-08
MX2017010412A (es) 2018-07-06
WO2016130986A1 (en) 2016-08-18
EP3256165B1 (en) 2021-07-14
ES2882157T3 (es) 2021-12-01
TW201636369A (zh) 2016-10-16
US10202453B2 (en) 2019-02-12
IL284336A (en) 2021-07-29
US20190127469A1 (en) 2019-05-02
EP4151231A1 (en) 2023-03-22
US20220002415A1 (en) 2022-01-06
IL292578A (en) 2022-06-01
CN108271359A (zh) 2018-07-10
MX2021007947A (es) 2021-08-16
JP2021054857A (ja) 2021-04-08
JP6917902B2 (ja) 2021-08-11
CN108271359B (zh) 2021-11-09
CA2976446A1 (en) 2016-08-18
EP3949984A1 (en) 2022-02-09
MX2022011935A (es) 2022-10-20
AU2016219170A1 (en) 2017-09-21
US20160237154A1 (en) 2016-08-18
JP2022084942A (ja) 2022-06-07
KR20180006367A (ko) 2018-01-17
IL253963B (en) 2021-07-29
EP3256165A4 (en) 2018-10-24
AU2016219170B2 (en) 2021-09-09
JP2018508573A (ja) 2018-03-29
WO2016130898A3 (en) 2016-10-20

Similar Documents

Publication Publication Date Title
AR103675A1 (es) Anticuerpos anti-ctla4 terapéuticos
CY1125260T1 (el) Παραγοντες δεσμευσης tigit και χρησεις τους
AR103867A1 (es) Anticuerpos contra inmunoglobulina y dominio 3 que contiene mucina de células t (anti-tim3), útiles como agentes terapéuticos
EA201891178A1 (ru) Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
EA201990594A1 (ru) Анти-tim-3 антитела и их применение
EA201892294A1 (ru) Антитела и композиции против tim-3
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
EA201790530A1 (ru) Агенты, связывающиеся с cd123, и виды их применения
MX2017010793A (es) Terapeuticos de anticuerpo que ligan cd137.
EA201791485A1 (ru) Анти-cd47-антитела и их применения
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
EA201891331A1 (ru) Бипаратопные полипептиды - антагонисты передачи сигнала wnt в опухолевых клетках
MX2015016111A (es) Anticuerpos anti-b7-h5 y sus usos.
EA201591611A1 (ru) Конъюгаты антитело-лекарственное средство
EA201892548A1 (ru) Антитела к альфа-синуклеину и их применение
EA201690504A1 (ru) Антигенсвязывающие белки к gitr
EA201591762A1 (ru) Человеческие антитела к grem1
PH12017500331A1 (en) Antigen binding proteins that bind cxcr5
EA201171374A1 (ru) Антитела против cd100 и способы их применения
UA123202C2 (uk) Антитіло до тау-білка і його застосування
EA201990778A1 (ru) Анти-il-33 антитела и их применение
MX2021000392A (es) Anticuerpos anti-mesotelina.
EA201891341A1 (ru) Антительно-цитокиновые привитые композиции и способы применения для иммунорегуляции
EA201591791A1 (ru) Антитела pac1 человека

Legal Events

Date Code Title Description
FB Suspension of granting procedure